UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A First Step To Enhance Step Counts In Women With Metastatic Breast Cancer: An Exploratory Study: 862

Medicine and science in sports and exercise, 2023-09, Vol.55 (9S), p.304-304

2023

Volltextzugriff (PDF)

A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA- mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1114-TPS1114

2022

Volltextzugriff (PDF)

Abstract PO2-19-04: Trial in Progress: The REJOIN Trial to Use Exercise and Education to Relieve Joint Pain in Older Breast Cancer Survivors Taking Aromatase Inhibitors

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-19-04-PO2-19-04

2024

Volltextzugriff (PDF)

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

The New England journal of medicine, 2015-03, Vol.372 (10), p.944-953

2015

Volltextzugriff (PDF)

Nurse AMIE: Addressing symptoms in rural patients with advanced cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS12148-TPS12148

2022

Volltextzugriff (PDF)

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

The lancet oncology, 2018-11, Vol.19 (11), p.1449-1458

2018

Volltextzugriff (PDF)

Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13014-e13014

2022

Volltextzugriff (PDF)

Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature

American journal of hematology, 2002-08, Vol.70 (4), p.320-323

2002

Volltextzugriff (PDF)

Role of the UGT2B17 deletion in exemestane pharmacogenetics

The pharmacogenomics journal, 2018-04, Vol.18 (2), p.295-300

2018

Volltextzugriff (PDF)

Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1030-1030

2021

Volltextzugriff (PDF)

A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1056-1056

2021

Volltextzugriff (PDF)

Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13018-e13018

2023

Volltextzugriff (PDF)

Abstract P1-19-30: Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-19-30

2020

Volltextzugriff (PDF)

Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.e364-e367

2019

Volltextzugriff (PDF)

UGT2B17 deletion polymorphism and exemestane-induced toxicity

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12534-e12534

2018

Volltextzugriff (PDF)

β-catenin affects androgen receptor transcriptional activity and ligand specificity

Cancer research (Chicago, Ill.), 2000-09, Vol.60 (17), p.4709-4713

2000

Volltextzugriff (PDF)

Write to recover: The impact of group led creative writing on behavioral health outcomes in cancer patients

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.11536-11536

2019

Volltextzugriff (PDF)

Abstract P5-13-10: Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-10

2022

Volltextzugriff (PDF)

Effect of creative writing on mood in cancer patients

Journal of clinical oncology, 2017-11, Vol.35 (31_suppl), p.178-178

2017

Volltextzugriff (PDF)

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Journal of thrombosis and haemostasis, 2015-03, Vol.13 (3), p.360-369

2015

Volltextzugriff (PDF)

The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis

Calcified tissue international, 2018-11, Vol.103 (5), p.567-580

2018

Volltextzugriff (PDF)

Adapting an Evidence-based Physical Activity Program for The REJOIN Trial for Older Breast Cancer Survivors

Innovation in aging, 2021-12, Vol.5 (Supplement_1), p.779-779

2021

Volltextzugriff (PDF)

HSR20-092: “Write to Recover”: The Impact of Group Led Creative Writing on Physical Health Outcomes in Cancer Patients

Journal of the National Comprehensive Cancer Network, 2020-03, Vol.18 (3.5), p.HSR20-092

2020

Volltextzugriff (PDF)

Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1067-1067

2020

Volltextzugriff (PDF)

26 – 50 von 68

Suche als RSS-Feed

Aktive Filter

KollektionDe Gruyter journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(67)
Tagungsberichte
(1)

Sprache

Englisch
(68)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(35)
Humans
(28)
Female
(19)
Oncology
(17)
Middle Aged
(15)
Aged
(13)
Breast Cancer
(10)
Male
(10)
Adult
(8)
Patients
(7)
Biological And Medical Sciences
(6)
Breast Neoplasms - Drug Therapy
(6)
Hematology
(6)
Medical Sciences
(6)
Tumors
(6)
Aged, 80 And Over
(5)
Antineoplastic Agents - Therapeutic Use
(5)
Cancer
(5)
Exercise
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A First Step To Enhance Step Counts In Women With Metastatic Breast Cancer: An Exploratory Study: 862

MECOM, HBS1L‐MYB, THRB‐RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients

Abstract PO2-19-04: Trial in Progress: The REJOIN Trial to Use Exercise and Education to Relieve Joint Pain in Older Breast Cancer Survivors Taking Aromatase Inhibitors

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Nurse AMIE: Addressing symptoms in rural patients with advanced cancer

Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen

Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: Case report and review of literature

Role of the UGT2B17 deletion in exemestane pharmacogenetics

Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen

A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer

Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor

Abstract P1-19-30: Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Pharmacokinetics of a new human plasma‐derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients

UGT2B17 deletion polymorphism and exemestane-induced toxicity

β-catenin affects androgen receptor transcriptional activity and ligand specificity

Write to recover: The impact of group led creative writing on behavioral health outcomes in cancer patients

Abstract P5-13-10: Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients

Effect of creative writing on mood in cancer patients

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis

Adapting an Evidence-based Physical Activity Program for The REJOIN Trial for Older Breast Cancer Survivors

HSR20-092: “Write to Recover”: The Impact of Group Led Creative Writing on Physical Health Outcomes in Cancer Patients

Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor)

Aktive Filter

Suchergebnisse filtern